Therapeutic Efficacy of Camrelizumab Plus Anlotinib on Advanced Non-Small Cell Lung Cancer
Objective To evaluate the efficacy of camrelizumab in advanced non-small cell lung cancer in combina-tion with anlotinib.Methods A total of seventy cases of advanced non-small cell lung cancer admitted to Rudong County People's Hospital from October 2022 to October 2023 were non-randomly selected as the study objects.Ac-cording to different treatment methods,they were divided into conventional group(single drug anlotinib treatment)and combined group(carrilitzumab combined with anlotinib treatment),with thirty-five cases in each group.Objective re-mission rate,disease control rate,incidence of adverse reactions and quality of life were compared between the two groups.Results There was no significant difference in the objective remission rate and disease control rate between the two groups(both P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(all P>0.05).The score of quality of life in the combined group was 78.63±4.85,which was higher than 71.36±6.98 of the conventional group,and the difference was statistically significant(t=5.060,P<0.05).Conclusion In the clinical treatment of advanced non-small cell lung cancer,carrilizumab combined with anlotinib is effective and can improve the quality of life of patients.
NETL
NSTL
万方数据
